BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

814 related articles for article (PubMed ID: 34733804)

  • 21. Assessing the impacts on fetal dosimetry of the modelling of the placental transfers of xenobiotics in a pregnancy physiologically based pharmacokinetic model.
    Codaccioni M; Brochot C
    Toxicol Appl Pharmacol; 2020 Dec; 409():115318. PubMed ID: 33160985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.
    De Sousa Mendes M; Lui G; Zheng Y; Pressiat C; Hirt D; Valade E; Bouazza N; Foissac F; Blanche S; Treluyer JM; Urien S; Benaboud S
    Clin Pharmacokinet; 2017 May; 56(5):537-550. PubMed ID: 27766562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and placental transfer of dolutegravir in pregnancy.
    Ikumi NM; Anumba D; Matjila M
    J Antimicrob Chemother; 2022 Feb; 77(2):283-289. PubMed ID: 34618029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacokinetics of antiarrhythmic agents in pregnancy and lactation.
    Mitani GM; Steinberg I; Lien EJ; Harrison EC; Elkayam U
    Clin Pharmacokinet; 1987 Apr; 12(4):253-91. PubMed ID: 3297463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling.
    Liu XI; Momper JD; Rakhmanina NY; Green DJ; Burckart GJ; Cressey TR; Mirochnick M; Best BM; van den Anker JN; Dallmann A
    Clin Pharmacokinet; 2020 Nov; 59(11):1433-1450. PubMed ID: 32451908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and Verification of a Linked
    Patilea-Vrana GI; Unadkat JD
    Drug Metab Dispos; 2021 Jul; 49(7):509-520. PubMed ID: 33952608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling.
    Schalkwijk S; Buaben AO; Freriksen JJM; Colbers AP; Burger DM; Greupink R; Russel FGM
    Clin Pharmacokinet; 2018 Jun; 57(6):705-716. PubMed ID: 28744795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of the betamethasone and dexamethasone dosing regimen during pregnancy: a combined placenta perfusion and pregnancy physiologically based pharmacokinetic modeling approach.
    Van Der Heijden JEM; Van Hove H; Van Elst NM; Van Den Broek P; Van Drongelen J; Scheepers HCJ; De Wildt SN; Greupink R
    Am J Obstet Gynecol; 2024 May; ():. PubMed ID: 38763343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses.
    Zhang Z; Imperial MZ; Patilea-Vrana GI; Wedagedera J; Gaohua L; Unadkat JD
    Drug Metab Dispos; 2017 Aug; 45(8):920-938. PubMed ID: 28588050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antidepressants and Antipsychotics in Human Pregnancy: Transfer Across the Placenta and Opportunities for Modeling Studies.
    Zheng L; Yang H; Dallmann A
    J Clin Pharmacol; 2022 Sep; 62 Suppl 1():S115-S128. PubMed ID: 36106784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diphenhydramine disposition in the sheep maternal-placental-fetal unit: gestational age, plasma drug protein binding, and umbilical blood flow effects on clearance.
    Kumar S; Tonn GR; Riggs KW; Rurak DW
    Drug Metab Dispos; 2000 Mar; 28(3):279-85. PubMed ID: 10681371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a Generic Fetal Physiologically Based Pharmacokinetic Model and Prediction of Human Maternal and Fetal Organ Concentrations of Cefuroxime.
    Liu XI; Green DJ; van den Anker J; Ahmadzia HK; Burckart GJ; Dallmann A
    Clin Pharmacokinet; 2024 Jan; 63(1):69-78. PubMed ID: 37962827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiologically based pharmacokinetic modeling to predict maternal pharmacokinetics and fetal carbamazepine exposure during pregnancy.
    Chen Y; Ke M; Fang W; Jiang Y; Lin R; Wu W; Huang P; Lin C
    Eur J Pharm Sci; 2024 Mar; 194():106707. PubMed ID: 38244810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance.
    Kumar S; Wong H; Yeung SA; Riggs KW; Abbott FS; Rurak DW
    Drug Metab Dispos; 2000 Jul; 28(7):845-56. PubMed ID: 10859159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments.
    Bukkems VE; van Hove H; Roelofsen D; Freriksen JJM; van Ewijk-Beneken Kolmer EWJ; Burger DM; van Drongelen J; Svensson EM; Greupink R; Colbers A
    Clin Pharmacokinet; 2022 Aug; 61(8):1129-1141. PubMed ID: 35579825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiologically-based pharmacokinetic models to predict drug exposure during pregnancy.
    Ait-Chikh C; Page G; Thoreau V
    Ann Pharm Fr; 2024 Mar; 82(2):236-242. PubMed ID: 37739215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating placental transfer and tissue concentrations of manganese in the pregnant rat and fetuses after inhalation exposures with a PBPK model.
    Yoon M; Nong A; Clewell HJ; Taylor MD; Dorman DC; Andersen ME
    Toxicol Sci; 2009 Nov; 112(1):44-58. PubMed ID: 19726578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimating fetal exposure to the P-gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome.
    Anoshchenko O; Milad MA; Unadkat JD
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1057-1070. PubMed ID: 34273255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug Transporters Expressed in the Human Placenta and Models for Studying Maternal-Fetal Drug Transfer.
    Dallmann A; Liu XI; Burckart GJ; van den Anker J
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1(Suppl 1):S70-S81. PubMed ID: 31502693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a physiologically based toxicokinetic model for lead in pregnant women: The role of bone tissue in the maternal and fetal internal exposure.
    Ali Daoud Y; Tebby C; Beaudouin R; Brochot C
    Toxicol Appl Pharmacol; 2023 Oct; 476():116651. PubMed ID: 37549741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.